JPM
JPMorgan Chase & Co.
JPM has a slight edge over MRSH overall, supported by stronger fundamentals and stronger modeled upside.
MRSH
Marsh & McLennan Companies, Inc.
MRSH offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
MRSH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MRSH's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MRSH.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
MRSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $206 | — |
| Cheap | 24x | $197 | -4.3% |
| Current | 25x | $206 | — |
| Fair | 27x | $229 | +12% |
| Expensive | 30x | $254 | +23% |
Historical ranges are pointers, not guarantees.
MRSH has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
MRSH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
MRSH has the edge over JPM on the outlook, with more favorable valuation expectations.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over MRSH on earnings, with more consistent year-over-year improvement.
MRSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.25 | +35% |
| Q3 2026 | $8.36 | +0.4% |
| Q2 2026 | $8.18 | -1.8% |
| Q1 2026 | $8.00 | -1.8% |
| Q4 2025 | $8.43 | +3.1% |
| Q3 2025 | $8.33 | +2.6% |
| Q2 2025 | $8.33 | +3.1% |
| Q1 2025 | $8.15 | +3.4% |
| Q4 2024 | $8.18 | +8.6% |
MRSH earned $8.36 per share over the past year, about the same as the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over MRSH on profitability, with a higher operating margin.
MRSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.9B | +8.1% |
| Q2 2026 | $7.4B | +6.2% |
| Q1 2026 | $7.6B | +7.6% |
| Q4 2025 | $6.6B | +8.7% |
| Q3 2025 | $6.4B | +11% |
| Q2 2025 | $7B | +12% |
| Q1 2025 | $7.1B | +9.1% |
| Q4 2024 | $6.1B | +9.2% |
MRSH has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | -0.7 points |
| Q2 2026 | 26% | -0.6 points |
| Q1 2026 | 23% | -5.3 points |
| Q4 2025 | 18% | -0.3 points |
| Q3 2025 | 18% | -1 points |
| Q2 2025 | 26% | -0.2 points |
| Q1 2025 | 28% | -1.3 points |
| Q4 2024 | 19% | -1 points |
MRSH's operating margin was 18% last quarter, down 0.7 points from the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
MRSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.4B | -30% |
| Q2 2026 | $1.5B | -10% |
| Q1 2026 | -$750M | -$73M |
| Q4 2025 | $2.1B | +9.4% |
| Q3 2025 | $2B | +9.3% |
| Q2 2025 | $1.6B | +42% |
| Q1 2025 | -$677M | +$191M |
| Q4 2024 | $1.9B | +13% |
MRSH has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
MRSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -3M shares |
| 1 year | -3% | -15M shares |
| 3 years | -4% | -20M shares |
| 5 years | -6.6% | -34M shares |
| Available history | -6.3% | -32M shares |
MRSH has 479M diluted shares, down 3% from a year ago, with $3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $504M |
| Q2 2026 | $757M |
| Q1 2026 | $755M |
| Q4 2025 | $1B |
| Q3 2025 | $402M |
| Q2 2025 | $300M |
| Q1 2025 | $300M |
| Q4 2024 | — |
MRSH spent $3B buying back its own shares over the past year, about three times what it spent the year before.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over MRSH on leverage, with a lower net debt burden relative to earnings.
MRSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 2.7x | Moderate |
MRSH's net debt is about 2.9 years of its operating earnings (EBITDA), up from 2.6 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MRSH.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
MRSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.6 | Neutral |
| Stochastic | 85.8 | Overbought |
MRSH's weekly RSI is 67 (neutral) and its Stochastic is 86 (overbought).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over MRSH on valuation relative to its sector.
MRSH PE vs Financial Services Sector
| Metric | MRSH | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 13x | 89% above |
| PE % | 22 | 63 | 41 pts below |
MRSH is trading at 25x earnings, a 89% premium to the Financial Services sector's median of 13x.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
MRSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $189.2 | 8.7% above |
| 20 week MA | $186.3 | 10% above |
| 50 week MA | $179.6 | 15% above |
| 100 week MA | $196.4 | 4.7% above |
| 200 week MA | $197.1 | 4.4% above |
MRSH has the edge over JPM on trend strength, trading above more of its moving averages.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
MRSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $112.0 | $115.1 | +2.8% |
| 2021 | $115.1 | $170.6 | +48% |
| 2022 | $170.6 | $165.6 | -2.9% |
| 2023 | $165.6 | $189.5 | +14% |
| 2024 | $189.5 | $213.5 | +13% |
| 2025 | $213.5 | $187.0 | -12% |
| 2026 YTD | $187.0 | $205.7 | +10% |
MRSH has the edge over JPM on returns for 2026, with the stronger performance.